Artificial Pancreas Market Size, Share and Growth Outlook, 2026

Artificial Pancreas Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Artificial Pancreas Market size is forecast to increase from $440.62 Million in 2026 to $1590.04 Million in 2034 at a CAGR of 17.4% between 2026 and 2034.

The Artificial Pancreas market report provides detailed analysis and outlook of Artificial Pancreas segments including By Device Component Type (Insulin Pumps, Continuous Glucose Monitoring, Control Algorithms & Software Apps), By System Mechanism (Insulin-Only Automated Delivery Systems, Dual-Hormone ), By Insurance (Private Insurance Covered, Public/Government Insurance Covered, Out-of-Pocket / Cash Pay), By End-User (Hospitals, Diabetes Clinics & Outpatient Centers, Homecare Settings, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Artificial Pancreas Industry Overview

Advancements in Automated Insulin Delivery Systems

The artificial pancreas industry is advancing rapidly as manufacturers develop increasingly sophisticated automated insulin delivery (AID) systems designed to improve glucose management for people with diabetes. Integration of continuous glucose monitoring technologies, adaptive insulin dosing algorithms, and intelligent software platforms is enhancing the effectiveness of closed-loop diabetes management. The industry is focused on reducing the burden of diabetes care while improving glycemic control through real-time automation and personalized treatment adjustments. Growing adoption of connected diabetes technologies is driving innovation across insulin pumps, sensors, and algorithm-driven therapeutic systems.

Integration of Advanced Sensors and Closed-Loop Technologies

A major trend shaping the artificial pancreas market is the integration of highly accurate glucose sensors with automated insulin delivery platforms. Medtronic announced the broad commercial launch of its latest MiniMed™ 780G system integrated with the Instinct™ sensor, developed in collaboration with Abbott. This milestone follows regulatory clearance for the first integration of the sensor into a fully automated insulin delivery system. The advancement strengthens the capability of closed-loop systems to continuously monitor glucose levels and automatically adjust insulin delivery, supporting more precise diabetes management and improved patient outcomes.

Personalized Diabetes Care Expanding Across Patient Populations

Manufacturers are increasingly tailoring artificial pancreas technologies to meet the needs of specific patient groups. Tandem’s Control-IQ+ automated insulin delivery system became the first FDA-cleared AID solution specifically indicated for use during pregnancy in women with Type 1 diabetes. The software enhancement for the t:slim X2 and Mobi insulin pumps provides tighter glucose targets that are critical for maternal and fetal health. Meanwhile, Sequel expanded access to its twiist™ system, which utilizes the Tidepool Loop algorithm and offers a unique circular tubed pump design for individuals aged six years and older with Type 1 diabetes. These developments highlight the industry's growing emphasis on personalized and patient-centric diabetes management solutions.

Competitive Innovation in Pump Technologies and Software Enhancements

The artificial pancreas market is witnessing increased competition as companies introduce new pump technologies and software-driven performance improvements. Insulet received FDA 510(k) clearance for enhancements to the Omnipod 5 system, including a lower target glucose setting of 100 mg/dL delivered through a remote software update. Such innovations enable users to achieve more individualized glucose control without requiring hardware replacement. At the same time, Beta Bionics announced plans to introduce its first insulin patch pump, Mint™, which will be compatible with the company’s adaptive insulin dosing algorithm. The upcoming launch is expected to intensify competition within the tubeless patch pump segment and further accelerate innovation in automated insulin delivery technologies.

Artificial Pancreas Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Artificial Pancreas market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Defymed SAS, Admetsys Corp., DreaMed Diabetes Ltd., Glytec, LLC. The Artificial Pancreas market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Artificial Pancreas industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Artificial Pancreas Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Artificial Pancreas companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Artificial Pancreas markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Artificial Pancreas Market Competitive Benchmarking and Company Analysis

Leading companies in Artificial Pancreas industry include- Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., F. Hoffmann-La Roche Ltd, Inreda Diabetic B.V., Defymed SAS, Admetsys Corp., DreaMed Diabetes Ltd., Glytec, LLC. The Artificial Pancreas market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Artificial Pancreas Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Artificial Pancreas market remains one of the strongest-performing segments in the country.
The US Artificial Pancreas Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Artificial Pancreas market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Artificial Pancreas industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Artificial Pancreas markets

Canada's strong Artificial Pancreas sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Artificial Pancreas market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Artificial Pancreas Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Artificial Pancreas market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Artificial Pancreas population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Artificial Pancreas industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Artificial Pancreas market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Artificial Pancreas sales through 2034

France Artificial Pancreas companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Artificial Pancreas Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Artificial Pancreas distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Artificial Pancreas Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Artificial Pancreas market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Artificial Pancreas industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Artificial Pancreas industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Artificial Pancreas Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Artificial Pancreas market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Artificial Pancreas market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Artificial Pancreas Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Artificial Pancreas Market Segmentation

By Device Component Type
Insulin Pumps
Continuous Glucose Monitoring
Control Algorithms & Software Apps
By System Mechanism
Insulin-Only Automated Delivery Systems
Dual-Hormone
By Insurance
Private Insurance Covered
Public/Government Insurance Covered
Out-of-Pocket / Cash Pay
By End-User
Hospitals
Diabetes Clinics & Outpatient Centers
Homecare Settings
Ambulatory Surgical Centers

Top Companies in Artificial Pancreas Industry

Medtronic plc
Insulet Corporation
Tandem Diabetes Care, Inc.
Beta Bionics, Inc.
F. Hoffmann-La Roche Ltd
Inreda Diabetic B.V.
Defymed SAS
Admetsys Corp.
DreaMed Diabetes Ltd.
Glytec, LLC

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025